Soluble CD14 (sCD14) mediates the response to lipopolysaccharide (LPS) in cells lacking membrane-bound CD14. We determined sCD14 concentrations in the sera of 38 periodontitis patients and 25 healthy controls by enzyme-linked immunosorbent assay. The sCD14 levels in the sera of patients with periodontitis were significantly higher than those of healthy subjects and decreased after treatment. Enhanced levels of sCD14 in serum may contribute to the host response to LPS in periodontitis. Furthermore, we showed in vitro that addition of LPS enhanced the release of sCD14 by monoblastic U937 cells treated with 1␣,25-dihydroxyvitamin D 3 . Thus, increased sCD14 levels in periodontitis patients may be due to chronic exposure to LPS.
Periodontitis, which is a major cause of tooth loss, is characterized by chronic inflammatory diseases caused by gramnegative bacteria (32) . The interaction of lipopolysaccharide (LPS) from gram-negative bacteria with host cells initiates the secretion of cytokines and the expression of cell adhesion molecules in gingival tissue (10, 28, 29) , leading to loss of the alveolar bone and connective tissue supporting the teeth in periodontitis. The CD14 molecule, which is expressed primarily on macrophages, reportedly mediates LPS-induced cell activation via binding of LPS (30, 33) . A soluble form of CD14 (sCD14) lacking the glycosylphosphatidylinositol anchor is also present in serum (3, 4) . Recent reports have demonstrated that sCD14 participates in LPS-induced activation of endothelial or epithelial cells that normally do not express membrane-bound CD14 (1, 2, 7, 8, 11, 22, 24) . In addition, in a previous study, we revealed that sCD14 mediates LPS-induced intercellular adhesion molecule 1 expression in cultured human gingival fibroblasts (9) . Thus, sCD14 may be important in the regulation of inflammatory and immunological responses in periodontitis. The present study is the first to investigate concentrations of sCD14 in the sera of patients with periodontitis.
We examined 38 patients with either adult periodontitis (AP; n ϭ 20; age range, 42 to 65 years) or early-onset periodontitis (EOP; n ϭ 18; age range, 16 to 41 years). A serum sample was obtained from the median cubital vein of each patient during the initial examination. Twenty-five periodontally healthy donors (age range, 20 to 34 years) served as controls. None of the subjects had any history of systemic diseases. The following clinical evaluations of each patient were performed: (i) measurement of probing pocket depth, (ii) determination of the number of residual teeth, and (iii) determination of the amount of bone loss. By using the method of Schei et al. (25) , alveolar bone resorption was measured on dental X-ray films. All of the periodontitis patients had periodontal pocket depths of greater than 5 mm involving at least four teeth and radiographic evidence of extensive bone resorption. To examine the effects of periodontal treatment on the sCD14 concentration in serum, we collected sera after active treatment from 16 of the 38 patients (9 with AP and 7 with EOP). These patients received oral hygiene instruction, scaling, and root planing. Subsequently, the patients were reevaluated as to the necessity of periodontal surgery. Twelve of the 16 patients received periodontal surgery. After the end of active treatment, the patients were reexamined. The treatment period ranged from 5 months to 5 years and 9 months (mean, 1 year and 11 months). In addition, we obtained serum samples from 5 of the 16 patients (1 with AP and 4 with EOP) at the reevaluation prior to periodontal surgery. All five of the patients received periodontal surgery.
The concentration of CD14 was measured by a sandwich enzyme-linked immunosorbent assay using two monoclonal antibodies (MAb) against different epitopes of sCD14 (IBL, Hamburg, Germany) in accordance with the manufacturer's instructions. In brief, serum specimens were diluted 1:101 and incubated in duplicate for 2 h in a 96-well plate precoated with the anti-CD14 MAb. The plate was incubated for 1 h with the other anti-CD14 MAb conjugated with peroxidase. Substrate was then added, and A 450 was measured by using a microtiter plate reader. The intra-and interassay coefficients of variation were 4.7 and 6.9%, respectively. Patient groups and controls were compared by one-way analysis of variance. For a comparison between pre-and posttreatment values, a paired t test was used. Correlations were assessed by using Spearman's correlation coefficient analysis. Comparisons of sCD14 release by U937 cells were carried out by using an unpaired t test.
As shown in Fig. 1 , the sCD14 concentration in serum was significantly higher in patients with periodontitis than in the healthy controls (3.22 versus 2.65 mg/liter; P Ͻ 0.01). When patients were classified as either AP or EOP, both groups showed significantly elevated sCD14 concentrations compared to the healthy controls (P Ͻ 0.01). There was no significant difference between AP and EOP. The levels of sCD14 in the control subjects were similar to those previously reported in control populations (6, 13, 15, (17) (18) (19) 31) . No correlation between the levels of sCD14 and the clinical variations of the patients was demonstrated (data not shown).
We then examined pre-and posttreatment sCD14 concentrations in the patients with periodontitis. The number of teeth with a probing pocket depth of more than 5 mm was significantly lower posttreatment than pretreatment (20.1 versus 2.7 teeth; P Ͻ 0.01), indicating clinical improvement. The sCD14 concentrations in serum following treatment were significantly lower than pretreatment levels (3.20 versus 2.67 mg/liter; P Ͻ 0.01) (Fig. 2) . At the level of the individual, 14 showed a decline in the sCD14 concentration and 2 showed an increase after treatment. The sCD14 concentrations of the patients after treatment were comparable to those of the healthy controls. Furthermore, we determined the sCD14 concentrations at the time of reevaluation prior to periodontal surgery in 5 of the 16 patients. All of the concentrations were lower than the pretreatment levels and higher than the posttreatment levels (Fig. 3) .
To elucidate the mechanism responsible for the enhancement of sCD14 levels in periodontitis patients, we further examined the effect of LPS on sCD14 release in 1␣,25-dihydroxyvitamin D 3 (VitD 3 )-treated U937 cells, which were reported previously to differentiate into monocytes and macrophages and to express CD14 on their surface (9, 12, 20) . U937 cells were originally obtained from the American Type Culture Collection (Manassas, Va.). The cells were maintained in RPMI 1640 medium (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% heat-inactivated fetal calf serum (GIBCO), 100 U of penicillin per ml, and 100 mg of streptomycin per ml in a humidified atmosphere of 5% CO 2 at 37°C. Cells were pretreated with 100 nM VitD 3 (Biomol Research Laboratories, Plymouth Meeting, Pa.) at a concentration of 2 ϫ 10 5 cells/ml for 24 h and then cultured for the specified times with medium containing LPS from Escherichia coli O55:B5 (Difco Laboratories, Detroit, Mich.). Concentrations of sCD14 in culture supernatants were determined by the above-mentioned sandwich enzyme-linked immunosorbent assay. As shown in Fig. 4 , sCD14 concentrations in supernatants of U937 cells treated with VitD 3 were continuously elevated during culture. Incubation with 0.1-or 100-ng/ml LPS resulted in a rise in sCD14 release which was statistically significant at 3 days compared with the control (P Ͻ 0.05).
We demonstrated that patients with periodontitis have elevated sCD14 concentrations in their serum. Recent studies suggest that sCD14 enables LPS to trigger responses by cells lacking cell surface CD14 (1, 2, 7-9, 11, 22, 24). We thus speculate that increased sCD14 in serum may contribute to heightened LPS responsiveness of CD14-negative cells, such as endothelial cells and fibroblasts, in periodontitis. Since no correlation was found between the levels of sCD14 and the clinical parameters of patients, it does not seem to be a suitable diag- nostic marker of periodontitis. However, the majority of patients showed a decline in sCD14 following treatment. The sCD14 concentrations decreased as the number of steps of treatment increased. Thus, sCD14 may be a useful complementary marker for monitoring each patient with periodontitis.
Serum sCD14 in periodontitis patients may originate from peripheral monocytes and macrophage in the gingival tissues. sCD14 is spontaneously released by monocytes and macrophages (14, 18) and constantly present in the serum of healthy persons (6, 13, 15, (17) (18) (19) 31) . The elevated sCD14 concentrations in periodontitis patient serum could be due to reduced sCD14 clearance or, alternatively, to enhanced liberation. The former is unlikely, because there may be no relationship between urinary output and periodontitis. The latter probably occurs during periodontitis. Consistent with other reports (14, 18) , we showed that LPS is a potent stimulator of sCD14 release from monocytes and macrophages. LPS of dental plaque has been shown to penetrate the gingiva (26) . Furthermore, bacteremia increases with increasing severity of gingival inflammation (27) , suggesting that periodontal infection leads to systemic exposure to gram-negative bacteria, LPS, and other bacterial products. Therefore, elevated LPS concentrations in the gingiva and bloodstream may account for increased CD14 release in vivo.
Several studies have demonstrated that the concentration of sCD14 in serum is elevated under pathological conditions, such as sepsis, AIDS, malaria, or systemic lupus erythematosus (6, 13, 15, (17) (18) (19) 31) . Most of these are systemic diseases. Periodontitis is known to be a long-standing chronic disease within a relatively small area of the body. That local periodontal infection upregulates the systemic sCD14 concentration in serum was an unexpected finding of the present study. Recent progress in bacterial classification and the realization that certain organisms are normally found only in the oral cavity have opened the way for a more accurate assessment of the risk of dental focal infection. Periodontal diseases are increasingly implicated in a variety of systemic disorders (5, 16, 23) . A recent report suggests that periodontal diseases represent a previously unrecognized and clinically significant risk factor for preterm low birth weight (21) . Thus, periodontal infections, which serve as reservoirs for gram-negative organisms, appear to pose a threat to systemic organs via transient bacteremia (27) or systemic changes such as an elevated level of sCD14 in serum.
